Log In
Print
BCIQ
Print
Print this Print this
 

CNV1014802

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionState-dependent inhibitor of sodium channel subunit Nav1.7 (SCN9A)
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNa channel blocker
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationPain
Indication DetailsTreat pain associated with lumbosacral radiculopathy; Treat pain associated with trigeminal neuralgia; Treat trigeminal neuralgia
Regulatory Designation U.S. - Orphan Drug (Treat trigeminal neuralgia)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$675.0M

$200.0M

$475.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today